公开(公告)号：JP2007302691A

公开(公告)日：2007-11-22

申请号：JP2007187127

申请日：2007-07-18

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B ,  HE YUN

IPC: C07D401/12 ,  A61K31/00 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P1/00 ,  A61P9/12 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/28 ,  A61P25/30 ,  A61P27/02 ,  A61P43/00 ,  C07D403/12 ,  C07D417/12

CPC classification number: C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: PROBLEM TO BE SOLVED: To provide a neuron nicotinic cholinergic compound selectively useful for the control of synapse transmission and provide a pharmaceutical composition containing the compound. SOLUTION: The invention relates to a new 3-pyridyloxymethyl heterocyclic ether of formula (I) and a pharmaceutical composition containing the compound in combination with a pharmacologically allowable carrier. In the formula, * is a chiral center; n is an integer selected from 1, 2 and 3; X is oxygen or sulfur; R 1 is hydrogen, allyl or a 1-6C alkyl; R 2 is hydrogen or CH2OH, CH2F, CH2CN or the like, when n=2; and A is methylene or ethylene which may be substituted with an alkyl group. COPYRIGHT: (C)2008,JPO&INPIT

Abstract translation: 待解决的问题：提供可选择性地用于控制突触传递的神经元烟碱性胆碱能化合物，并提供含有该化合物的药物组合物。 解决方案：本发明涉及式（I）的新的3-吡啶氧基甲基杂环醚和含有与药理学上允许的载体组合的化合物的药物组合物。 在公式中，*是手性中心; n是选自1,2和3的整数; X是氧或硫; R 1是氢，烯丙基或1-6C烷基; 当n = 2时，R SP 2是氢或CH 2 OH，CH 2 F，CH 2 CN等; 并且A是可被烷基取代的亚甲基或亚乙基。 版权所有（C）2008，JPO＆INPIT

公开(公告)号：JP2009143924A

公开(公告)日：2009-07-02

申请号：JP2008327771

申请日：2008-12-24

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： HOLLADAY MARK W ,  ARNERIC STEPHEN P ,  BAI HAO ,  DART MICHAEL J ,  LIN NAN-HORNG ,  LYNCH JOHN K ,  OR YAT SUN ,  RYTHER KEITH B ,  SULLIVAN JAMES P ,  WASICAK JAMES T ,  EHRLICH PAUL P

IPC: A61P25/04 ,  C07D401/12 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/485 ,  A61P9/10 ,  A61P25/28 ,  A61P29/00 ,  A61P43/00 ,  C07D205/04 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D401/12 ,  A61K31/4427 ,  A61K31/485 ,  C07D205/04 ,  Y02P20/55 ,  A61K2300/00

Abstract: PROBLEM TO BE SOLVED: To provide a new 3-pyridyl enantiomer. SOLUTION: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering selected compounds of formula I or a pharmaceutically acceptable salt thereof to a mammal or patient in need of treatment thereof. The invention further relates to selected (R) and (S) compounds of formula I which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatory agents. COPYRIGHT: (C)2009,JPO&INPIT

Abstract translation: 要解决的问题：提供新的3-吡啶基对映异构体。 解决方案：本发明涉及一种控制包括人在内的哺乳动物疼痛的方法，其包括给选择的式I化合物或其药学上可接受的盐施用于需要治疗的哺乳动物或患者。 本发明还涉及可用作止痛剂的选择的（R）和（S）化合物，以及神经元细胞死亡预防剂和抗炎剂。 版权所有（C）2009，JPO＆INPIT

公开(公告)号：JP2007269811A

公开(公告)日：2007-10-18

申请号：JP2007153768

申请日：2007-06-11

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： ELLIOTT RICHARD L ,  RYTHER KEITH B ,  HOLLADAY MARK W ,  WASICAK JAMES T ,  DAANEN JEROME F

IPC: C07D491/048 ,  A61K31/00 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/4355 ,  A61P9/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/28 ,  A61P25/30 ,  A61P25/32 ,  A61P25/34 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044 ,  C07D495/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/4355 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04

Abstract: PROBLEM TO BE SOLVED: To provide furopyridine, thienopyridine, pyrrolopyridine, and related pyrimidine, pyridazine and triazine compounds controlling chemical synaptic transmission; to provide medicinal compositions of the compounds effective for therapy; and to provide these compositions for selectively controlling the synaptic transmission. SOLUTION: The novel heterocyclic ether compound is represented by formula (I) (wherein, A, m, R, X, Y 1 , Y 2 and Y 3 are specifically defined). The medicinal composition thereof is effective for the therapy. The compositions are used for selectively controlling the synaptic transmission in mammals. COPYRIGHT: (C)2008,JPO&INPIT

Abstract translation: 要解决的问题：提供控制化学突触传播的呋喃啶，噻吩并吡啶，吡咯并吡啶和相关的嘧啶，哒嗪和三嗪化合物; 提供有效治疗的化合物的药物组合物; 并提供这些组合物以选择性地控制突触传递。 解决方案：新型杂环醚化合物由式（I）表示（其中，A，m，R，X，Y 1 ，Y 2， SP> 3 是特别定义的）。 其药物组合物对于治疗是有效的。 组合物用于选择性地控制哺乳动物的突触传递。 版权所有（C）2008，JPO＆INPIT

公开(公告)号：WO2007140439A3

公开(公告)日：2008-01-24

申请号：PCT/US2007070029

申请日：2007-05-31

Applicant: ABBOTT LAB ,  DART MICHAEL J ,  CARROLL WILLIAM A ,  FLORJANCIC ALAN S ,  FROST JENNIFER M ,  GALLAGHER MEGAN E ,  KOLASA TEODOZYJ ,  LI TONGMEI ,  NELSON DEREK W ,  PATEL MEENA V ,  PEDDI SRIDHAR ,  PEREZ-MEDRANO ARTURO ,  RYTHER KEITH B ,  TIETJE KARIN ROSEMARIE

Inventor： DART MICHAEL J ,  CARROLL WILLIAM A ,  FLORJANCIC ALAN S ,  FROST JENNIFER M ,  GALLAGHER MEGAN E ,  KOLASA TEODOZYJ ,  LI TONGMEI ,  NELSON DEREK W ,  PATEL MEENA V ,  PEDDI SRIDHAR ,  PEREZ-MEDRANO ARTURO ,  RYTHER KEITH B ,  TIETJE KARIN ROSEMARIE

IPC: C07D277/46 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61P29/00 ,  C07D277/48 ,  C07D277/82 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D493/08

CPC classification number: C07D277/46 ,  A61K31/429 ,  C07D277/48 ,  C07D277/82 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D493/08 ,  C07D513/04

Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , R 4 , and L 2 , are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，前体药物，前药盐或其组合，其中R 1，R 2，R 2， 在本说明书中定义了含有这些化合物的组合物，以及使用这些化合物治疗病症和障碍的方法，其中，R 3，R 4， 和组合物。

公开(公告)号：WO2007140385A2

公开(公告)日：2007-12-06

申请号：PCT/US2007069921

申请日：2007-05-30

Applicant: ABBOTT LAB ,  DART MICHAEL J ,  CARROLL WILLIAM A ,  FLORJANCIC ALAN S ,  FROST JENNIFER M ,  GALLAGHER MEGAN E ,  LI TONGMEI ,  NELSON DEREK W ,  PATEL MEENA V ,  PEDDI SRIDHAR ,  PEREZ-MEDRANO ARTURO ,  RYTHER KEITH B ,  TIETJE KARIN ROSEMARIE ,  KOLASA TEODOZYJ

Inventor： DART MICHAEL J ,  CARROLL WILLIAM A ,  FLORJANCIC ALAN S ,  FROST JENNIFER M ,  GALLAGHER MEGAN E ,  LI TONGMEI ,  NELSON DEREK W ,  PATEL MEENA V ,  PEDDI SRIDHAR ,  PEREZ-MEDRANO ARTURO ,  RYTHER KEITH B ,  TIETJE KARIN ROSEMARIE ,  KOLASA TEODOZYJ

CPC classification number: C07D277/82 ,  C07D277/46 ,  C07D277/48 ,  C07D277/60 ,  C07D417/06 ,  C07D417/12 ,  C07D477/14 ,  C07D513/04

Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2 , R3 , R4 , and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Abstract translation: 本发明涉及式（I）化合物或其药物盐，前体药物，前体药物或其组合的盐，其中R1，R2，R3，R4和L1在具体实施方案中定义，包含这些化合物的组合物和方法 使用这些化合物和组合物治疗病症和病症。 本发明还涉及式（II）化合物或其药物盐，前药，前体药物或其组合的盐，其中R 1a，R 2a和（R x）n如说明书中所定义，包含这些化合物的组合物和方法 使用这些化合物和组合物治疗病症和病症。

公开(公告)号：EP2222165A4

公开(公告)日：2011-01-05

申请号：EP08852528

申请日：2008-11-20

Applicant: ABBOTT LAB

Inventor： FLORJANCIC ALAN S ,  DART MICHAEL J ,  RYTHER KEITH B ,  PEREZ-MEDRANO ARTURO ,  CARROLL WILLIAM A ,  PATEL MEENA V ,  TIETJE KARIN ROSEMARIE ,  LI TONGMEI ,  KOLASA TEODOZYJ ,  GALLAGHER MEGAN E ,  PEDDI SRIDHAR ,  FROST JENNIFER M ,  NELSON DEREK W

IPC: C07D277/46

CPC classification number: C07D417/12 ,  C07D277/46 ,  C07D417/06 ,  C07D513/04 ,  C07D513/20

公开(公告)号：CA2223062C

公开(公告)日：2010-10-12

申请号：CA2223062

申请日：1996-05-28

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B ,  HE YUN

IPC: C07D401/12 ,  A61K31/00 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P25/00 ,  A61P25/04 ,  C07D403/12 ,  C07D417/12

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds having formula (I), wherein * is a chiral center and n, X, R1, R2, A andB are specifically defined, which are useful in controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions therof; and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：MX2010005649A

公开(公告)日：2010-08-18

申请号：MX2010005649

申请日：2008-11-20

Applicant: ABBOTT LAB

Inventor： DART MICHAEL J ,  GALLAGHER MEGAN E ,  RYTHER KEITH B ,  LI TONGMEI ,  CARROLL WILLIAM A ,  PEREZ-MEDRANO ARTURO ,  FLORJANCIC ALAN S ,  NELSON DEREK W ,  KOLASA TEODOZYJ ,  PATEL MEENA V ,  FROST JENNIFER M ,  PEDDI SRIDHAR ,  TIETJE KARIN ROSEMARIE

IPC: A01N43/42

Abstract: La presente invención se refiere a compuestos de la fórmula (I), o sales farmacéuticas, profármacos, sales de profármaco, o combinaciones de los mismos, fórmula (I), en donde R1, R2, R3, R4, y L1 se definen en la especificación, composiciones que comprenden dichos compuestos, y métodos para el tratamiento de condiciones y trastornos utilizando dichos compuestos y composiciones. La presente invención también se refiere a compuestos de la fórmula (II), o sales farmacéuticas, profármacos, sales de profármacos, o combinaciones de los mismos, fórmula (II), en donde R1a, R2a, Rx, y n son como se define en la especificación, composiciones que comprenden dichos compuestos, y métodos para el tratamiento de condiciones y trastornos utilizando dichos compuestos y composiciones.

公开(公告)号：AU2004274492B2

公开(公告)日：2010-04-29

申请号：AU2004274492

申请日：2004-09-17

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  DART MICHAEL J ,  TIETJE KARIN R ,  SCHRIMPF MICHAEL R ,  RYTHER KEITH B ,  GALLAGHER MEGAN E ,  NERSESIAN DIANA L ,  MORTELL KATHLEEN H ,  PACE JENNIFER M ,  BASHA ANWER ,  JI JIANGUO

IPC: A61K31/435 ,  A61P25/00 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5-or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazoyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ±7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

公开(公告)号：ES2305373T3

公开(公告)日：2008-11-01

申请号：ES03017562

申请日：2000-01-25

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  BARLOCCO CRISTINA DANIELA ,  DAANEN JEROME F ,  DART MICHAEL J ,  MEYER MICHAEL D ,  RYTHER KEITH B

IPC: C07D487/08 ,  A61K31/00 ,  A61K31/395 ,  A61K31/407 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/502 ,  A61P9/10 ,  A61P15/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D401/08 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

Abstract: Un compuesto de fórmula (Ver fórmula) o una sal farmacéuticamente aceptable del mismo, en la que: Z es CH2CH2; L1 se selecciona entre el grupo compuesto por un enlace covalente y (CH2)n; n es 1-5; R1 se selecciona entre el grupo compuesto por (Ver fórmulas) R2 se selecciona entre el grupo compuesto por hidrógeno, alcoxicarbonilo, alquilo, aminoalquilo, aminocarbonilalquilo, benciloxicarbonilo, cianoalquilo, dihidro-3-piridinilcarbonilo, hidroxi, hidroxialquilo, fenoxicarbonilo, y -NH2; R4 se selecciona entre el grupo compuesto por hidrógeno, alquilo, y halógeno; R5 se selecciona entre el grupo compuesto por hidrógeno, alcoxi, alquilo, halógeno, nitro, y -NH2; R6 se selecciona entre el grupo compuesto por hidrógeno, alquenilo, alcoxi, alcoxialcoxi, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquilcarbonilo, alquilcarboniloxi, alquiltio, alquinilo, aminoalquilo, amino-carbonilo, aminocarbonilalquilo, aminosulfonilo, carboxi, carboxialquilo, ciano, cianoalquilo, formilo, formilalquilo, haloalcoxi, haloalquilo, halógeno, hidroxi, hidroxialquilo, mercapto, mercaptoalquilo, nitro, 5-tetrazolilo, -NR7SO2R8, NR10R11, en las que R10 y R11 son hidrógeno, alquilo, alquilcarbonilo y formilo. -C(NR7)NR7R8, -CH2C(NR7)NR7R8, -C(NOR7)R8, -C(NCN)R7, -C(NNR7R8)R8, -S(O)2OR7, y -S(O)2R7; y R7 y R8 se seleccionan independientemente entre el grupo compuesto por hidrógeno y alquilo.